Kanghong Pharma has initiated the phase 1 clinical trial of KH801, a humanized anti-CD24 antibody, in patients with solid tumors. The China NMPA cleared the IND application of KH801 in March 2024. The first-in-human study was estimated to enroll 17-42 patients with 7 dose groups. Targeting the CD24-Siglec10 Axis KH801 KH801 eliminates tumor cells through Fc-mediated immune response and by inhibiting CD24/Siglec10 signaling in both. CD24, a small membrane protein heavily glycosylated and anchored by GPI, interacts with Siglec-10 on TAMs (Tumor-Associated Macrophages) to act as a 'don't eat me' signal, aiding tumor cells in evading macrophage engulfment. CD24 is prevalent across various solid tumors. In 2021, Kanghong applied for a patent ( WO2023104066 ) for using the anti-CD24 antibody or an antigen-binding fragment to treat tumors or immune diseases. Kanghong presented the preclinical study results at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meet
China Biotech XYZ Shares Updates Related to New Drug Development in China